Business Wire

KIRIN Develops Technology to Enhance Heat and Drought Tolerance in Hop Seedlings Contributing to a Sustainable Supply of Beer Ingredients Amid Climate Change

26.9.2025 03:44:00 CEST | Business Wire | Press Release

Share

Kirin Holdings Company, Limited (Kirin) (TOKYO: 2503) has developed a seedling cultivation technology that enhances heat and drought tolerance in hops through acquired tolerance, helping to address the growing challenges of reduced yield and quality caused by extreme heat and drought. This method enables hops to gain resilience without compromising flavor quality, and is expected to contribute to a more sustainable and stable supply of beer ingredients. This technology was presented at the Scientific-Technical Commission of the International Hop Growers' Convention in June 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924957521/en/

Field trial in Iwate Prefecture. Variety: Saaz. Left: untreated control plants; Right: heat-treated plants.

Background of the Research

  • Global warming is known to act as heat stress on plants, inhibiting their growth*1. Hops, which prefer cool climates, suffer from poor growth under high temperatures and dry conditions, leading to declining yields and quality worldwide. This raises concerns about rising raw material costs and impacts on product quality, necessitating the development of technologies enabling stable cultivation and procurement even under climate change.

*1 In plants, temperatures higher than their optimal growth range cause heat stress. This can lead to delayed growth and symptoms such as leaf whitening.

Research Overview

  • Leveraging Kirin’s long-standing expertise in plant cultivation technologies*2 , we have developed a seedling production technique to induce heat tolerance and drought tolerance in hop seedlings. This is achieved by growing the seedlings in a liquid medium and applying a six-week heat treatment at 25°C during the mass propagation process. Unlike traditional breeding or genetic modification, this technique allows hops to acquire resilience without altering their original aroma or flavor profile. This research was evaluated using the Czech variety “Saaz” and the German variety “Hersbrucker.”

*2 Kirin Succeeds in Developing the World’s First Technology to Promote Axillary Bud Formation in Hops—A Breakthrough in Mass Propagation of Hop Plants (Website in Japanese)

Research Findings

Laboratory evaluation of high-temperature and dry environments

  • In laboratory tests simulating high-temperature and drought-conditions*3, heat-treated hop plants exhibited significantly higher plant height and chlorophyll*4 content compared to untreated control plants, demonstrating improved growth and enhanced tolerance.

*3 Drought condition testing was conducted using the “Saaz” variety only.
*4 Chlorophyll is a natural green pigment essential for photosynthesis. As leaves wither, they turn white or yellow due to reduced chlorophyll levels.

Cultivation evaluation at the test field

  • In cultivation evaluations conducted in Esashi City, Iwate Prefecture, heat-treated hop plants showed significantly higher plant height and above-ground weight compared to untreated control plants, and tended to produce higher cone yields.

Future Outlook

  • Moving forward, we will advance the refinement of mass seedling production technology, elucidate physiological changes induced by heat treatment, and verify applicability across multiple fields and varieties, while exploring implementation overseas. Our company aims to contribute to the realization of a sustainable beer ingredient supply.

The Kirin Group will continue to tackle complex and interrelated environmental issues (biological resources, water resources, containers and packaging, and climate change) in an integrated manner, and to work together with all those involved in the value chain to link our desire to enjoy and pass on the bounty of the Earth’s abundance to future generations. We will actively promote various initiatives that have a ‘positive impact’ on nature and people.

Reference: Kirin’s Environmental Initiatives

Kirin Group's Environmental Vision 2050 | The Environment | KIRIN - Kirin Holdings Company, Limited
Kirin Group Environmental Report | Sustainability Information | KIRIN - Kirin Holdings Company, Limited

Attachment: "Research Findings"

Background and Objective

  • Hops are a dioecious vine plant belonging to the Cannabaceae family. The female flowers, known as strobili, contain diverse secondary metabolites that impart bitterness, aroma, and antimicrobial properties to beer, making them an essential ingredient in brewing. Hops are plants that prefer cool climates and are primarily cultivated in regions between 35° and 55° north and south latitude, such as Europe, North America, and Australia. In response to recent declines in hop yield and quality due to rising temperatures and drought, accelerating Research and Development on climate change adaptation—including breeding improvements and cultivation techniques—to achieve sustainable raw material procurement has become an urgent priority.

Research Methodology

  • Methods for conferring stress tolerance to plants include breeding, genetic modification, the use of biostimulants, and environmental condition control. This study selected environmental condition control, as it is expected to have minimal impact on flavor. Specifically, we developed a technique to confer acquired heat and drought tolerance by growing hop seedlings in liquid medium and applying a six-week heat treatment at 25°C during the propagation process. This study evaluated the Czech variety “Saaz” and the German variety “Hersbrucker”.

Research Findings

1. Stress Tolerance Evaluation in Laboratory Conditions

  • In tests conducted under both high-temperature and drought-conditions *5, heat-treated hop plants showed significantly higher plant height and chlorophyll content compared to untreated control plants, confirming improved growth and enhanced tolerance.

*5 Drought condition testing was conducted using the “Saaz” variety only.

2. Field Evaluation in Japan

  • In April 2023, heat-treated plants and untreated control plants were planted in Esashi City and Tono City, both located in Iwate Prefecture, and evaluated over a two-year period.
  • In Esashi City, where the average temperature from May to September is approximately 2°C higher than in Tono City, heat-treated plants showed a significant tendency toward larger aboveground weight and higher boll yield compared to untreated control plants. No significant difference was observed in Tono City, where temperatures are lower than in Esashi City.

About Kirin Holdings

Kirin Holdings Company, Limited is an international company that operates in the Food & Beverages domain (Food & Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses), and Health Science domain (Health Science business), both in Japan and across the globe.

Kirin Holdings can trace its roots to Japan Brewery which was established in 1885. Japan Brewery became Kirin Brewery in 1907. Since then, the company expanded its business with fermentation and biotechnology as its core technologies, and entered the pharmaceutical business in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as a pure holding company and is currently focusing on boosting its Health Science domain.

Under the Kirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become “A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals.” Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.

*: Creating Shared Value. Combined added value for consumers as well as for society at large.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250924957521/en/

Contacts

Press Contact
Corporate Communication Department
Kirin Holdings Company, Limited
Nakano Central Park South, 4-10-2 Nakano, Nakano-ku, Tokyo
+81-3-6837-7028
Media Inquiries | KIRIN - Kirin Holdings Company, Limited -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffaq.kirin.co.j
p%2Fform%2Fkh_10_en.html&esheet=54329484&newsitemid=20250924957521&lan=en-US&anc
hor=Media+Inquiries+%7C+KIRIN+-+Kirin+Holdings+Company%2C+Limited&index=4&md5=e7
0dc75e6cff94d774c8ebf778c2ed72
https://www.kirinholdings.com/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kirinholdi
ngs.com%2Fen%2F&esheet=54329484&newsitemid=20250924957521&lan=en-US&anchor=https
%3A%2F%2Fwww.kirinholdings.com%2Fen%2F&index=5&md5=6d6b12e38f8b7be88f6cd17d2c9a9
57e
kirin-cc@kirin.co.jp

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye